Multiple Sclerosis Drugs Market Future Scope and Trends in the United States

The global multiple sclerosis drugs market size was worth USD 23.68 billion in 2021. The market valuation is projected to increase from USD 25.43 billion in 2022 to USD 33.17 billion by 2029 at a CAGR of 3.9% during 2022-2029. In recent years, the incidence of multiple sclerosis has increased significantly. According to the Multiple Sclerosis International Federation, the number of multiple sclerosis patients reached 2.8 million in 2020, up from 2.3 million in 2013. Increasing federal funding and accelerated R&D efforts to address the increasing occurrence of multiple sclerosis will positively impact the market growth.

Request a Sample Copy of Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386

Regional Insights-

North America to Hold Dominant Share Led by Expanding R&D

North America dominated the global multiple sclerosis drugs market share in 2021 with a revenue worth USD 11.36billion. Key factors supporting the regional growth are increasing R&D and novel product launches.

The European market is anticipated to hold the second largest share in the market, supported by active government investments and a favorable reimbursement scenario. Meanwhile, the market in Asia Pacific will be driven by the growing number of collaborations between biotech companies.

Competitive Landscape-

Major Market Players Seek Regulatory Approvals to Expand Market Share

Leading players involved in the development of multiple sclerosis drugs include Biogen and F. Hoffmann-La Roche Ltd. Growing R&D and regulatory approvals for novel solutions are key factors for the dominance of these companies. For instance, Biogen received the marketing approval from the European Commision for the injection of TYSABRI (natalizumab) in April 2021. Other key players include Sanofi, Novartis AG, and MErck KGaA.

List of Key Market Players:

●       Biogen (U.S.)

●       Pfizer Inc. (U.S.)

●       F. Hoffmann-La Roche Ltd. (Switzerland)

●       Novartis AG (Switzerland)

●       Merck & Co., Inc. (U.S.)

●       Sanofi (France)

●       Teva Pharmaceutical Industries Ltd. (Israel)

●       Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)

●       Bristol-Myers Squibb Company (U.S.)

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

  

Comments

Post a Comment

Popular posts from this blog

Interventional Cardiology Devices Market Size, Share, Growth and Demand

  Interventional Cardiology Devices Market Size, Share & COVID-19 Impact Analysis, By Type (Coronary Vascular Devices and Structural Heart Devices), By Product (Coronary Stents, Heart Valve Therapy Devices, Angioplasty Balloons, Atherectomy Devices, Intravascular Ultrasound (IVUS) Devices, and Others), By End User (Hospitals & Ambulatory Surgical Centers and Clinics & Others), and Regional Forecasts, 2022-2029 The global interventional cardiology devices market size was valued at USD 13.67 billion in 2021. The market is projected to grow from USD 14.61 billion in 2022 to USD 23.61 billion by 2029, exhibiting a CAGR of 7.1% during the forecast period. Prevalence of Cardiovascular Diseases (CVDs) such as coronary heart disease, stroke, and atrial fibrillation to propel the market progression . There is focus on the production and launch of advanced devices to meet the growing demand for minimally invasive devices. Fortune Business Insights ™ shares this information ...
Read more

Veterinary Diagnostics Market Growth in United States

  The global veterinary diagnostics market size is projected to reach USD 9.5 billion by 2026, exhibiting a CAGR of 10.0% during the forecast period. Rising prevalence of zoonotic diseases such as swine flu and rabies is the main factor driving the growth of this market. Zoonotic diseases are those which humans contract from animals, birds or insects. They pose grave danger not only to the person infected, but also to other people who might come in close contact with him or her, laying the groundwork for an epidemic. A study published by the Centers for Disease Control and Prevention (CDC) states that 75% of emerging infectious diseases affecting humans are zoonotic in origin. This was already witnessed during the recent Ebola outbreak and rapid spread of swine flu a few years earlier. Preventing the birth of such diseases is crucial for public health as they also cause huge economic losses. According to the WHO, zoonotic epidemics between 1997 and 2009 led to a loss of about USD 8...
Read more

Autoinjectors Industry Size 2024-2030

  The global " Autoinjectors Market Size 2024 ” Forecast to 2030 research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The Autoinjectors Market report also examines the current state of the industry, as well as predicted future growth, technological advancements, investment prospects, market economics, and financial data. Get a sample PDF of the report at -  https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/108507 The global autoinjectors market size was USD 102.51 billion in 2022. The market is projected to grow from USD 111.16 billion in 2023 to USD 233.69 billion by 2030, exhibiting a CAGR of 11.2% during the forecast period. Autoinjectors Market Competitive Analysis: The Autoinjectors Market report examines competitive sc...
Read more